The role of β3-integrins in tumor angiogenesis: Context is everything

Current Opinion in Cell Biology

Volumn 23, Issue 5, 2011, Pages 630-637

  Robinson, Stephen D ^a   Hodivala Dilke, Kairbaan M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; CILENGITIDE; GROWTH FACTOR RECEPTOR; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ANGIOGENESIS; CELL INTERACTION; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR ANGIOGENESIS;

ANIMALS; CELL ADHESION MOLECULES; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRIN BETA3; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 80053374576     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2011.03.014     Document Type: Review

References (89)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6:273-286.
2. Nussenbaum F., Herman I.M. Tumor angiogenesis: insights and innovations. J Oncol 2010, 2010:132641.
3. Ruoslahti E., Pierschbacher M.D. New perspectives in cell adhesion: RGD and integrins. Science 1987, 238:491-497.
4. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
5. Humphries J.D., Byron A., Humphries M.J. Integrin ligands at a glance. J Cell Sci 2006, 119:3901-3903.
6. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
7. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
8. Van Waes C. Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Head Neck 1995, 17:140-147.
9. Kumar C.C. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003, 4:123-131.
10. Alghisi G.C., Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 2006, 13:113-135.
11. Cai W., Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 2006, 6:407-428.
12. Carter A. Integrins as target: first phase III trial launches, but questions remain. J Natl Cancer Inst 2010, 102:675-677.
13. Ruegg C., Alghisi G.C. Vascular integrins: therapeutic and imaging targets of tumor angiogenesis. Recent Results Cancer Res 2010, 180:83-101.
14. Hodivala-Dilke K. alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. Curr Opin Cell Biol 2008, 20:514-519.
15. Stupack D.G., Puente X.S., Boutsaboualoy S., Storgard C.M., Cheresh D.A. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 2001, 155:459-470.
16. Alghisi G.C., Ponsonnet L., Ruegg C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS ONE 2009, 4:e4449.
17. Smith J.W. Cilengitide merck. Curr Opin Investig Drugs 2003, 4:741-745.
18. Reynolds L.E., Wyder L., Lively J.C., Taverna D., Robinson S.D., Huang X., Sheppard D., Hynes R.O., Hodivala-Dilke K.M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002, 8:27-34.
19. Mechtersheimer G., Barth T., Hartschuh W., Lehnert T., Moller P. In situ expression of beta 1, beta 3 and beta 4 integrin subunits in non-neoplastic endothelium and vascular tumours. Virchows Arch 1994, 425:375-384.
20. Sato T., Konishi K., Kimura H., Maeda K., Yabushita K., Tsuji M., Miwa A. Vascular integrin beta 3 and its relation to pulmonary metastasis of colorectal carcinoma. Anticancer Res 2001, 21:643-647.
21. Sato T., Miwa A. Ets-1 and integrin beta3 for lung metastasis from colorectal cancer. APMIS 2002, 110:347-353.
22. Nisato R.E., Tille J.C., Jonczyk A., Goodman S.L., Pepper M.S. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003, 6:105-119.
23. Buerkle M.A., Pahernik S.A., Sutter A., Jonczyk A., Messmer K., Dellian M. Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 2002, 86:788-795.
24. Yamada S., Bu X.Y., Khankaldyyan V., Gonzales-Gomez I., McComb J.G., Laug W.E. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 2006, 59:1304-1312. discussion 1312.
25. Loges S., Butzal M., Otten J., Schweizer M., Fischer U., Bokemeyer C., Hossfeld D.K., Schuch G., Fiedler W. Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Biochem Biophys Res Commun 2007, 357:1016-1020.
26. Stupp R., Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007, 25:1637-1638.
27. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
28. Reynolds A.R., Hart I.R., Watson A.R., Welti J.C., Silva R.G., Robinson S.D., Da Violante G., Gourlaouen M., Salih M., Jones M.C., et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009, 15:392-400.
29. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
30. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111:1287-1295.
31. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
32. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L.M., Carbone D.P., Lin P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421.
33. Khakoo A.Y., Finkel T. Endothelial progenitor cells. Annu Rev Med 2005, 56:79-101.
34. Peters B.A., Diaz L.A., Polyak K., Meszler L., Romans K., Guinan E.C., Antin J.H., Myerson D., Hamilton S.R., Vogelstein B., et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005, 11:261-262.
35. Grunewald M., Avraham I., Dor Y., Bachar-Lustig E., Itin A., Jung S., Chimenti S., Landsman L., Abramovitch R., Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006, 124:175-189.
36. Jin D.K., Shido K., Kopp H.G., Petit I., Shmelkov S.V., Young L.M., Hooper A.T., Amano H., Avecilla S.T., Heissig B., et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006, 12:557-567.
37. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
38. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
39. Italiano J.E., Richardson J.L., Patel-Hett S., Battinelli E., Zaslavsky A., Short S., Ryeom S., Folkman J., Klement G.L. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008, 111:1227-1233.
40. Rafii D.C., Psaila B., Butler J., Jin D.K., Lyden D. Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow-derived cells. Arterioscler Thromb Vasc Biol 2008, 28:217-222.
41. Tucker K.L., Sage T., Stevens J.M., Jordan P.A., Jones S., Barrett N.E., St-Arnaud R., Frampton J., Dedhar S., Gibbins J.M. A dual role for integrin-linked kinase in platelets: regulating integrin function and alpha-granule secretion. Blood 2008, 112:4523-4531.
42. Wall C.D., Conley P.B., Armendariz-Borunda J., Sudarshan C., Wagner J.E., Raghow R., Jennings L.K. Expression of alpha IIb beta 3 integrin (GPIIb-IIIa) in myeloid cell lines and normal CD34+/CD33+ bone marrow cells. Blood Cells Mol Dis 1997, 23:361-376.
43. Umemoto T., Yamato M., Shiratsuchi Y., Terasawa M., Yang J., Nishida K., Kobayashi Y., Okano T. Expression of Integrin beta3 is correlated to the properties of quiescent hemopoietic stem cells possessing the side population phenotype. J Immunol 2006, 177:7733-7739.
44. Kieffer N., Phillips D.R. Platelet membrane glycoproteins: functions in cellular interactions. Annu Rev Cell Biol 1990, 6:329-357.
45. Shattil S.J. Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost 1995, 74:149-155.
46. Horton M.A. The alpha v beta 3 integrin 'vitronectin receptor'. Int J Biochem Cell Biol 1997, 29:721-725.
47. Eliceiri B.P., Cheresh D.A. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999, 103:1227-1230.
48. Eliceiri B.P., Cheresh D.A. Adhesion events in angiogenesis. Curr Opin Cell Biol 2001, 13:563-568.
49. Taverna D., Moher H., Crowley D., Borsig L., Varki A., Hynes R.O. Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins. Proc Natl Acad Sci U S A 2004, 101:763-768.
50. Mahabeleshwar G.H., Feng W., Phillips D.R., Byzova T.V. Integrin signaling is critical for pathological angiogenesis. J Exp Med 2006, 203:2495-2507.
51. Weis S.M., Lindquist J.N., Barnes L.A., Lutu-Fuga K.M., Cui J., Wood M.R., Cheresh D.A. Cooperation between VEGF and beta3 integrin during cardiac vascular development. Blood 2007, 109:1962-1970.
52. Watson A.R., Pitchford S.C., Reynolds L.E., Direkze N., Brittan M., Alison M.R., Rankin S., Wright N.A., Hodivala-Dilke K.M. Deficiency of bone marrow beta3-integrin enhances non-functional neovascularization. J Pathol 2010, 220:435-445.
53. Feng W., McCabe N.P., Mahabeleshwar G.H., Somanath P.R., Phillips D.R., Byzova T.V. The angiogenic response is dictated by beta3 integrin on bone marrow-derived cells. J Cell Biol 2008, 183:1145-1157.
54. Brill A., Elinav H., Varon D. Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res 2004, 63:226-235.
55. Morgan E.A., Schneider J.G., Baroni T.E., Uluckan O., Heller E., Hurchla M.A., Deng H., Floyd D., Berdy A., Prior J.L., et al. Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit. FASEB J 2010, 24:1117-1127.
56. Hagemann T., Lawrence T., McNeish I., Charles K.A., Kulbe H., Thompson R.G., Robinson S.C., Balkwill F.R. Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008, 205:1261-1268.
57. Kaur S., Kenny H.A., Jagadeeswaran S., Zillhardt M.R., Montag A.G., Kistner E., Yamada S.D., Mitra A.K., Lengyel E. {beta}3-Integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol 2009, 175:2184-2196.
58. Carreiras F., Denoux Y., Staidly C., Lehmann M., Sichel F., Gauduchon P. Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 1996, 62:260-267.
59. Maubant S., Cruet-Hennequart S., Dutoit S., Denoux Y., Crouet H., Henry-Amar M., Gauduchon P. Expression of alpha V-associated integrin beta subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens. J Mol Histol 2005, 36:119-129.
60. Lorger M., Krueger J.S., O'Neal M., Staflin K., Felding-Habermann B. Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci U S A 2009, 106:10666-10671.
61. Harburger D.S., Calderwood D.A. Integrin signalling at a glance. J Cell Sci 2009, 122:159-163.
62. Mitra S.K., Hanson D.A., Schlaepfer D.D. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005, 6:56-68.
63. Giannone G., Sheetz M.P. Substrate rigidity and force define form through tyrosine phosphatase and kinase pathways. Trends Cell Biol 2006, 16:213-223.
64. Ginsberg M.H., Partridge A., Shattil S.J. Integrin regulation. Curr Opin Cell Biol 2005, 17:509-516.
65. Legate K.R., Montanez E., Kudlacek O., Fassler R: I.L.K. PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 2006, 7:20-31.
66. Deakin N.O., Turner C.E. Paxillin comes of age. J Cell Sci 2008, 121:2435-2444.
67. Ziegler W.H., Liddington R.C., Critchley D.R. The structure and regulation of vinculin. Trends Cell Biol 2006, 16:453-460.
68. Liu S., Calderwood D.A., Ginsberg M.H. Integrin cytoplasmic domain-binding proteins. J Cell Sci 2000, 113(Pt 20):3563-3571.
69. Zaidel-Bar R., Itzkovitz S., Ma'ayan A., Iyengar R., Geiger B. Functional atlas of the integrin adhesome. Nat Cell Biol 2007, 9:858-867.
70. Somanath P.R., Ciocea A., Byzova T.V. Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem Biophys 2009, 53:53-64.
71. Jones P.L., Crack J., Rabinovitch M. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol 1997, 139:279-293.
72. Borges E., Jan Y., Ruoslahti E. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J Biol Chem 2000, 275:39867-39873.
73. Trusolino L., Serini G., Cecchini G., Besati C., Ambesi-Impiombato F.S., Marchisio P.C., De Filippi R. Growth factor-dependent activation of alphavbeta3 integrin in normal epithelial cells: implications for tumor invasion. J Cell Biol 1998, 142:1145-1156.
74. Rahman S., Patel Y., Murray J., Patel K.V., Sumathipala R., Sobel M., Wijelath E.S. Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. BMC Cell Biol 2005, 6:8.
75. Vuori K., Ruoslahti E. Association of insulin receptor substrate-1 with integrins. Science 1994, 266:1576-1578.
76. Delafontaine P., Song Y.H., Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004, 24:435-444.
77. Bahr C., Groner B. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 2005, 23:1-14.
78. Clemmons D.R., Maile L.A., Ling Y., Yarber J., Busby W.H. Role of the integrin alphaVbeta3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress. Growth Horm IGF Res 2007, 17:265-270.
79. Beauvais D.M., Ell B.J., McWhorter A.R., Rapraeger A.C. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 2009, 206:691-705.
80. Beauvais D.M., Rapraeger A.C. Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. J Cell Sci 2010, 123:3796-3807.
81. Soldi R., Mitola S., Strasly M., Defilippi P., Tarone G., Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 1999, 18:882-892.
82. Masson-Gadais B., Houle F., Laferriere J., Huot J. Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones 2003, 8:37-52.
83. Mahabeleshwar G.H., Chen J., Feng W., Somanath P.R., Razorenova O.V., Byzova T.V. Integrin affinity modulation in angiogenesis. Cell Cycle 2008, 7:335-347.
84. Mahabeleshwar G.H., Feng W., Reddy K., Plow E.F., Byzova T.V. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 2007, 101:570-580.
85. Reynolds A.R., Reynolds L.E., Nagel T.E., Lively J.C., Robinson S.D., Hicklin D.J., Bodary S.C., Hodivala-Dilke K.M. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res 2004, 64:8643-8650.
86. Robinson S.D., Reynolds L.E., Wyder L., Hicklin D.J., Hodivala-Dilke K.M. Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler Thromb Vasc Biol 2004, 24:2108-2114.
87. Robinson S.D., Reynolds L.E., Kostourou V., Reynolds A.R., da Silva R.G., Tavora B., Baker M., Marshall J.F., Hodivala-Dilke K.M. Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. J Biol Chem 2009, 284:33966-33981.
88. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
89. Zachary I., Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001, 49:568-581.